3.6644

0.43% 0.0244

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $3.6644, with a volume of 4.96M. It is up +0.43% in the last 24 hours and down -7.69% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Previous Close:

$3.64

Open:

$3.68

24h Volume:

4.96M

Relative Volume:

0.32

Market Cap:

$1.51B

Revenue:

$263.44M

Net Income/Loss:

$-390.98M

P/E Ratio:

-3.2689

EPS:

-1.121

Net Cash Flow:

$-336.24M

1W Performance:

+5.35%

1M Performance:

-7.69%

6M Performance:

+63.19%

1Y Performance:

+13.17%

1-Day Range:

$3.53

$3.71

1-Week Range:

$3.42

$4.31

52-Week Range:

$1.6385

$5.63

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (622)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

975

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA Iovance Biotherapeutics Inc	3.665	1.50B	263.44M	-390.98M	-336.24M	-1.121
VRTX Vertex Pharmaceuticals Inc	439.74	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	740.60	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	837.86	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	332.17	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	314.80	34.41B	5.36B	287.73M	924.18M	2.5229

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform
Jul-15-25	Downgrade	Goldman	Neutral → Sell
May-16-25	Downgrade	UBS	Buy → Neutral
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

Apr 13, 2026

REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN

Apr 13, 2026

Apr 11, 2026

IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance B - GuruFocus

Apr 11, 2026

Macro Review: Will Iovance Biotherapeutics Inc benefit from green energy policiesDividend Hike & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Apr 11, 2026

REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits

Apr 11, 2026

IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN

Apr 11, 2026

Iovance Biotherapeutics: Analyzing Growth Potential and Risks After Amtagvi Approval - IndexBox

Apr 11, 2026

Iovance Biotherapeutics (IOVA) Is Up 16.9% After Stronger Real-World Amtagvi Data Spurs Franchise Hopes - Sahm

Apr 11, 2026

IOVA Maintained by Chardan Capital -- Price Target Stays at $16 - GuruFocus

Apr 11, 2026

Apr 10, 2026

IOVA Stock Grinds Sideways As Traders Weigh Heavy Losses - timothysykes.com

Apr 10, 2026

Iovance Biotherapeutics Faces Stock Decline Amid Market Dynamics - Intellectia AI

Apr 10, 2026

Jefferies reiterates Iovance Biotherapeutics stock rating at buy By Investing.com - Investing.com Canada

Apr 10, 2026

Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

Apr 10, 2026

IOVA: Analyst Comments on FDA Rejection Impact - GuruFocus

Apr 10, 2026

Iovance Biotherapeutics (IOVA) Maintains Strong Outlook Amid Reg - GuruFocus

Apr 10, 2026

Iovance Biotherapeutics Faces Market Waves Amid Losses and Strategic Moves - timothysykes.com

Apr 10, 2026

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - Yahoo Finance

Apr 10, 2026

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - The Motley Fool

Apr 10, 2026

IOVA Stock Holds Key Support As Biotech Traders Circle - StocksToTrade

Apr 10, 2026

IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill

Apr 10, 2026

Apr 09, 2026

Iovance’s Landmark FDA Approval Shakes Up Melanoma Treatment Market - StocksToTrade

Apr 09, 2026

A Look At Iovance Biotherapeutics (IOVA) Valuation After Strong Amtagvi Data And Growing Pipeline Momentum - Sahm

Apr 09, 2026

Apr 08, 2026

Analyst sentiment remains strong on Iovance Biotherapeutics (IOVA) amid US rollout of melanoma drug, Amtagvi - MSN

Apr 08, 2026

Aug Fed Impact: How correlated is Iovance Biotherapeutics Inc to the S P5002026 Top Gainers & Community Shared Stock Ideas - baoquankhu1.vn

Apr 08, 2026

Market Review: How correlated is Iovance Biotherapeutics Inc to the S P500Portfolio Performance Summary & Low Risk High Reward Ideas - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving AverageHere's What Happened - MarketBeat

Apr 07, 2026

Apr 06, 2026

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA) - Seeking Alpha

Apr 06, 2026

Apr 04, 2026

IOVA SEC FilingsIovance Biotherp 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 04, 2026

Apr 03, 2026

Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today? - Meyka

Apr 03, 2026

Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed? - Sahm

Apr 03, 2026

Apr 02, 2026